From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma

Immunotherapy has revolutionized the treatment landscape for many cancer types. The treatment for renal cell carcinoma (RCC) has especially evolved in recent years, from cytokine-based immunotherapies to immune checkpoint inhibitors. Although clinical benefit from immunotherapy is limited to a subse...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jonathan Anker, Justin Miller, Nicole Taylor, Natasha Kyprianou, Che-Kai Tsao
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	renal cell carcinoma tumor microenvironment immunology immunotherapy Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/951e1e7f7a2f46bbb26efa30f2a3f187
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:951e1e7f7a2f46bbb26efa30f2a3f187
record_format	dspace
spelling	oai:doaj.org-article:951e1e7f7a2f46bbb26efa30f2a3f1872021-11-25T17:13:06ZFrom Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma10.3390/cells101132312073-4409https://doaj.org/article/951e1e7f7a2f46bbb26efa30f2a3f1872021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3231https://doaj.org/toc/2073-4409Immunotherapy has revolutionized the treatment landscape for many cancer types. The treatment for renal cell carcinoma (RCC) has especially evolved in recent years, from cytokine-based immunotherapies to immune checkpoint inhibitors. Although clinical benefit from immunotherapy is limited to a subset of patients, many combination-based approaches have led to improved outcomes. The success of such approaches is a direct result of the tumor immunology knowledge accrued regarding the RCC microenvironment, which, while highly immunogenic, demonstrates many unique characteristics. Ongoing translational work has elucidated some of the mechanisms of response, as well as primary and secondary resistance, to immunotherapy. Here, we provide a comprehensive review of the RCC immunophenotype with a specific focus on how preclinical and clinical data are shaping the future of immunotherapy.Jonathan AnkerJustin MillerNicole TaylorNatasha KyprianouChe-Kai TsaoMDPI AGarticlerenal cell carcinomatumor microenvironmentimmunologyimmunotherapyBiology (General)QH301-705.5ENCells, Vol 10, Iss 3231, p 3231 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	renal cell carcinoma tumor microenvironment immunology immunotherapy Biology (General) QH301-705.5
spellingShingle	renal cell carcinoma tumor microenvironment immunology immunotherapy Biology (General) QH301-705.5 Jonathan Anker Justin Miller Nicole Taylor Natasha Kyprianou Che-Kai Tsao From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma
description	Immunotherapy has revolutionized the treatment landscape for many cancer types. The treatment for renal cell carcinoma (RCC) has especially evolved in recent years, from cytokine-based immunotherapies to immune checkpoint inhibitors. Although clinical benefit from immunotherapy is limited to a subset of patients, many combination-based approaches have led to improved outcomes. The success of such approaches is a direct result of the tumor immunology knowledge accrued regarding the RCC microenvironment, which, while highly immunogenic, demonstrates many unique characteristics. Ongoing translational work has elucidated some of the mechanisms of response, as well as primary and secondary resistance, to immunotherapy. Here, we provide a comprehensive review of the RCC immunophenotype with a specific focus on how preclinical and clinical data are shaping the future of immunotherapy.
format	article
author	Jonathan Anker Justin Miller Nicole Taylor Natasha Kyprianou Che-Kai Tsao
author_facet	Jonathan Anker Justin Miller Nicole Taylor Natasha Kyprianou Che-Kai Tsao
author_sort	Jonathan Anker
title	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma
title_short	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma
title_full	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma
title_fullStr	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma
title_full_unstemmed	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma
title_sort	from bench to bedside: how the tumor microenvironment is impacting the future of immunotherapy for renal cell carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/951e1e7f7a2f46bbb26efa30f2a3f187
work_keys_str_mv	AT jonathananker frombenchtobedsidehowthetumormicroenvironmentisimpactingthefutureofimmunotherapyforrenalcellcarcinoma AT justinmiller frombenchtobedsidehowthetumormicroenvironmentisimpactingthefutureofimmunotherapyforrenalcellcarcinoma AT nicoletaylor frombenchtobedsidehowthetumormicroenvironmentisimpactingthefutureofimmunotherapyforrenalcellcarcinoma AT natashakyprianou frombenchtobedsidehowthetumormicroenvironmentisimpactingthefutureofimmunotherapyforrenalcellcarcinoma AT chekaitsao frombenchtobedsidehowthetumormicroenvironmentisimpactingthefutureofimmunotherapyforrenalcellcarcinoma
_version_	1718412605749460992

From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma

Ejemplares similares